Current trends in the development of new antidepressants

被引:99
作者
Pacher, P [1 ]
Kohegyi, E
Kecskemeti, V
Furst, S
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol & Cell Biol, JAH, Philadelphia, PA 19107 USA
[2] Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, H-1085 Budapest, Hungary
关键词
D O I
10.2174/0929867013373796
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Early antidepressant medications e.g. tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are effective because they enhance either noradrenergic or serotonergic mechanisms, or both. Unfortunately, these compounds block cholinergic, histaminergic and proportional to 1-adrenergic receptor sites, interact with a number of other medications and bring about numerous undesirable side effects. Several chemically unrelated agents have been developed and introduced in the past decade to supplement the early antidepressants. These include selective inhibitors of the reuptake of serotonin (the selective serotonin reuptake inhibitors (SSRIs)) or noradrenaline (reboxetine) or both (SNRIs: milnacipran and venlafaxine), as well as drugs with distinct neurochemical profiles such as mirtazapine, nefazodone, moclobemide and tianeptine. All these newer compounds are the results of rational developmental strategies to find drugs that were as effective as the TCAs but of higher safety and tolerability profile. In spite of the remarkable structural diversity, most currently introduced antidepressants are 'monoamin based' and modulating monoamine activity as a therapeutic strategy continues to dominate antidepressant research. It must be emphasised, however, that these newer antidepressants are far from the ideal ones, also resulting in undesirable side effects and requiring 2-6 weeks of treatment to produce therapeutic effect. Furthermore, approximately 30% of the population do not respond to current therapies. An important new development has been the emergence of potential novel mechanisms of action beyond the monoaminergic synapse. The results of recent novel developmental approaches have suggested that modulation of N-methyl-D-aspartate (NMDA), neuropeptide (substance P and corticotrophin-releasing factor) receptors and the intracellular messenger system may provide an entirely new set of potential therapeutic targets. This paper discusses the advances from monoamine-based treatment strategies and looks at the future developments in the treatment of depression.
引用
收藏
页码:89 / 100
页数:12
相关论文
共 110 条
[1]   Neurotrophins and depression [J].
Altar, CA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (02) :59-61
[2]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[3]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[4]  
ARTIGAS F, 1994, ARCH GEN PSYCHIAT, V51, P248
[5]  
Baldessarini RJ, 1996, GOODMAN GILMANS PHAR
[6]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[7]   CLINICAL PHARMACOKINETICS OF CITALOPRAM AND OTHER SELECTIVE SEROTONERGIC REUPTAKE INHIBITORS (SSRI) [J].
BAUMANN, P .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 6 :13-20
[8]   FLUVOXAMINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BENFIELD, P ;
WARD, A .
DRUGS, 1986, 32 (04) :313-334
[9]  
BLAZER DG, 1994, AM J PSYCHIAT, V151, P979
[10]   1-ARYL-2-(AMINOMETHYL)CYCLOPROPANECARBOXYLIC ACID-DERIVATIVES - A NEW SERIES OF POTENTIAL ANTIDEPRESSANTS [J].
BONNAUD, B ;
COUSSE, H ;
MOUZIN, G ;
BRILEY, M ;
STENGER, A ;
FAURAN, F ;
COUZINIER, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (02) :318-325